• About
• Links
• Contact
• Sitemap

Endo Pharmaceuticals’ Lidoderm - Physician survey indicates increased use likely to fuel sales

Launched in the US in 1999 as the only topical lidocaine patch, Lidoderm has demonstrated very strong growth year-on-year, with annual growth of 114% in 2003, 73% in 2004, and 36% in 2005. Lidoderm’s continued growth in both labeled and off-label indications is highly important to the company’s future success.

Scope

Report Highlights
Surveyed physicians expect to continue to increase their use of Lidoderm in post-herpetic neuralgia and a variety of off-label pain conditions with use varying by specialty.

The largest barriers to use of Lidoderm are price and reimbursement but some physicians believe the situation is improving.

Near-term competitive threats are not expected to substantially derail Lidoderm’s growth rate.

Reasons to Purchase

Table of Contents

• SUMMARY - page 1
  • Physician survey indicates increased use of Lidoderm likely to fuel above-consensus sales growth - page 1
• ENDO PHARMACEUTICALS - page 5
  • Overview - page 5
• LIDODERM - page 5
  • Lidoderm is the only topical lidocaine patch available in the US - page 5
  • Lidoderm is FDA-approved in post-herpetic neuralgia but has data in other pain indications - page 5
  • Five years post-launch, Lidoderm sales are still showing strong growth - page 6
• PHYSICIAN SURVEY BACKGROUND - page 7
  • Pain specialists are the highest prescribers of Lidoderm - page 7
• USE OF LIDODERM - page 7
  • Indication and specialty - page 7
  • Physicians report increasing use of Lidoderm on- and off-label - page 7
  • All surveyed physician types expect to prescribe greater volumes of Lidoderm - page 9
  • Lidoderm continues to penetrate approved indication and low back pain, its largest off-label condition - page 9
    • In PHN, pain specialists have leveled off use at 60% of patients, while other specialists predict increases - page 9
    • Lidoderm share of low back pain market expected to expand across all physician types - page 10
• DRIVERS OF LIDODERM'S GROWTH - page 11
  • Survey results indicate Lidoderm growth fueled by both new and existing prescribers - page 11
  • Growing physician familiarity and appreciation of benign safety profile drive use - page 12
  • Increased marketing and publication of off-label data also spur growth - page 12
  • Lidoderm detailing has become more frequent, especially for neurologists - page 13
  • Price and reimbursement barriers exist, but some physicians report improvements - page 13
  • Pfizer's Lyrica, a recent entrant to pain market poses little competitive threat - page 14
  • Efficacy results from ongoing low back pain trial likely to only be moderately important - page 14
• LIDODERM FORECAST - page 15
  • We forecast sustainable growth, ahead-of-consensus sales - page 15
• APPENDIX - page 17
  • Datamonitor Healthcare - page 17
  • Disclosure information - page 17
  • Ask the analyst - page 18


• List of Tables
• Table 1: Post-marketing data released on Lidoderm in chronic pain conditions - page 5
• Table 2: Historic Lidoderm sales 1999-2005 - page 6
• Table 3: Breakdown of surveyed physicians by specialty - page 7
• Figure 1: Average number of prescriptions per month of Lidoderm by indication - page 8
• Figure 2: Average number of prescriptions per month of Lidoderm by physician specialty - page 9
• Table 4: Average penetration of Lidoderm in PHN according to time and physician specialty - page 10
• Table 5: Average penetration of Lidoderm in low back pain according to time and physician specialty - page 11
• Figure 3: Impact of treatment settings on sales growth on a scale of 1 to 5, where 1 = no impact, 5= strong impact - page 12
• Figure 4: Most commonly identified factors behind Lidoderm sales growth (percentage of physicians) - page 13
• Figure 5: Physician expectation of the impact of Lyrica on Lidoderm use (percent of physicians) - page 14
• Figure 6: Physician expectation of the impact that negative trial results from ongoing Phase II low back pain trial would have on Lidoderm use (percentage of physicians) - page 15
• Table 6: US Lidoderm sales forecast 2006-2008 - page 16

Other users found this report page using the following search terms: endo Lidoderm lidocaine phn pain lidoderm pharmaceutical label off costs user agent endometriosis price sales

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.